日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The HKDC1-ASS1-ACSBG2 axis reprograms lipid metabolism to drive therapeutic resistance in hepatocellular carcinoma

HKDC1-ASS1-ACSBG2轴重编程脂质代谢,从而驱动肝细胞癌的治疗耐药性。

Ling, Xiangyu; Zhao, Wenhu; Li, Kuan; Liang, Litao; Jia, Wenbo; Wang, Jinyi; Feng, Yanzhi; Xu, Chao; Lv, Qingpeng; Feng, Zhiwen; Zhu, Deming; Kong, Lianbao; Ding, Wenzhou

TTC36-Mediated Tumor Suppression via YBX3/SPRED1 Axis Paradoxically Reduces Sorafenib Sensitivity in Hepatocellular Carcinoma

TTC36通过YBX3/SPRED1轴介导的肿瘤抑制作用反而降低了肝细胞癌对索拉非尼的敏感性

Zhao, Wenhu; Ling, Xiangyu; Li, Kuan; Liang, Litao; Jia, Wenbo; Wang, Jinyi; Feng, Yanzhi; Xu, Chao; Lv, Qingpeng; Zhu, Deming; Feng, Zhiwen; Ai, Xiaoming; Kong, Lianbao; Ding, Wenzhou

Predicting hepatocellular carcinoma outcomes and immune therapy response with ATP-dependent chromatin remodeling-related genes, highlighting MORF4L1 as a promising target

利用ATP依赖性染色质重塑相关基因预测肝细胞癌预后和免疫治疗反应,重点关注MORF4L1这一有前景的靶点

Xu, Chao; Liang, Litao; Liu, Guoqing; Feng, Yanzhi; Xu, Bin; Zhu, Deming; Jia, Wenbo; Wang, Jinyi; Zhao, Wenhu; Ling, Xiangyu; Zhou, Yongping; Ding, Wenzhou; Kong, Lianbao

Dynamic microphysiological system chip platform for high-throughput, customizable, and multi-dimensional drug screening

用于高通量、可定制、多维药物筛选的动态微生理系统芯片平台

Yuxuan Zhu, Deming Jiang, Yong Qiu, Xin Liu, Yuhan Bian, Shichao Tian, Xiandi Wang, K Jimmy Hsia, Hao Wan, Liujing Zhuang, Ping Wang

HNF4A-AS1 inhibits the progression of hepatocellular carcinoma by promoting the ubiquitin-modulated degradation of PCBP2 and suppressing the stability of ARG2 mRNA.

HNF4A-AS1 通过促进 PCBP2 的泛素调节降解和抑制 ARG2 mRNA 的稳定性来抑制肝细胞癌的进展

Jia Wenbo, Yu Liang, Xu Bin, Feng Yanzhi, Wang Jinyi, Zhu Deming, Xu Chao, Liang Litao, Zhou Yongping, Kong Lianbao, Ding Wenzhou

Vertical impedance electrode array for spatiotemporal dynamics monitoring of 3D cells under drug diffusion effect

垂直阻抗电极阵列用于药物扩散作用下三维细胞时空动态监测

Yong Qiu, Xin Liu, Yuxuan Zhu, Deming Jiang, Fengheng Li, Weijie Yu, Hao Wan, Liujing Zhuang, Yuxiang Pan, Ping Wang

Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study

瑞戈非尼联合免疫检查点抑制剂疗法作为晚期肝细胞癌患者二线和三线治疗方案的疗效和安全性:一项回顾性研究

Zhao, Jie; Guo, Yongzhong; Feng, Tianshuo; Rong, Dawei; Kong, Xiangyi; Huang, Tian; Lopez-Lopez, Victor; Yarmohammadi, Hooman; Sakamoto, Yoshihiro; Zhu, Deming; Yao, Aihua; Xia, Yongxiang

Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/ nuclear factor -kappa B (NF-κB) pathway

癌相关成纤维细胞外泌体通过 circZFR 靶向信号转导和转录激活因子 (STAT3)/核因子-κB (NF-κB) 通路,促进肝细胞癌对顺铂的化疗耐药性。

Zhou, Yun; Tang, Weiwei; Zhuo, Han; Zhu, Deming; Rong, Dawei; Sun, Jin; Song, Jinhua

Genistein Restricts the Epithelial Mesenchymal Transformation (EMT) and Stemness of Hepatocellular Carcinoma via Upregulating miR-1275 to Inhibit the EIF5A2/PI3K/Akt Pathway

染料木素通过上调 miR-1275 抑制 EIF5A2/PI3K/Akt 通路,从而限制肝细胞癌的上皮间质转化 (EMT) 和干性

Yang, Xiao; Jiang, Wangjie; Kong, Xiangxu; Zhou, Xiao; Zhu, Deming; Kong, Lianbao

LINC00173 promotes Wilms' tumor progression through MGAT1-mediated MUC3A N-glycosylation

LINC00173 通过 MGAT1 介导的 MUC3A N-糖基化促进 Wilms 肿瘤进展

Qingliang Zhu, Deming Zhan, Yongguo Yang, Yankun Chong, Haoliang Xue, Peng Zhu